Ursula A Matulonis
Overview
Explore the profile of Ursula A Matulonis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
210
Citations
10738
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pozzar R, Tulsky J, Berry D, Batista J, Barwick P, Lindvall C, et al.
JMIR Cancer
. 2025 Mar;
11:e66801.
PMID: 40063817
Background: People with advanced ovarian cancer and their caregivers report unmet supportive care needs. We developed a Collaborative Agenda-Setting Intervention (CASI) to elicit patients' and caregivers' needs through the patient...
2.
Tyan K, Liu K, Smart A, Feltmate C, Horowitz N, Muto M, et al.
Gynecol Oncol
. 2025 Mar;
195:75-81.
PMID: 40058185
Background: There are limited data around adjuvant radiotherapy following surgical management for patients with early-stage uterine carcinosarcoma (UCS). We compared outcomes for patients with early-stage UCS who underwent adjuvant chemotherapy...
3.
Straczkiewicz M, Keating N, Schonholz S, Matulonis U, Horowitz N, Campos S, et al.
medRxiv
. 2025 Feb;
PMID: 39974129
Objective: This study evaluated the feasibility of using smartphone-based metrics to monitor physical functioning and quality of life in patients with advanced gynecological cancers. We analyzed associations between gait (step...
4.
Yang Z, Mogre S, Jun H, He R, Ghosh Chaudhary S, Bhattarai U, et al.
Cancer Res Commun
. 2025 Feb;
PMID: 39932274
In the United States, Endometrial carcinoma (EC) is the most frequently occurring gynecologic cancer. Many ECs harbor mutations in cell cycle regulatory genes including TP53 and RB1, amongst others. RB...
5.
Lin L, Irshaid L, Matulonis U, Kolin D
Int J Gynecol Pathol
. 2025 Jan;
PMID: 39869066
Ovarian clear cell carcinoma (OCCC) is an endometriosis-related neoplasm, in which traditional histologic grading does not show prognostic significance. Tumor budding was associated with poorer outcomes in OCCC in previous...
6.
Bogani G, Moore K, Ray-Coquard I, Lorusso D, Matulonis U, Ledermann J, et al.
Gynecol Oncol
. 2025 Jan;
193:30-40.
PMID: 39764856
Objective: Therapeutic interventions for epithelial ovarian cancer (EOC) have increased greatly over the last decade but improvements outside of biomarker selected therapies have been limited. There remains a pressing need...
7.
Cham S, Pozzar R, Horowitz N, Feltmate C, Matulonis U, Lai J, et al.
J Geriatr Oncol
. 2024 Dec;
16(2):102173.
PMID: 39708401
Introduction: We performed a qualitative study to explore key stakeholders' perspectives about the impact of frailty on ovarian cancer care and evaluate a candidate prehabilitation intervention. Materials And Methods: We...
8.
Moore K, Lorusso D, Oaknin A, Oza A, Colombo N, Van Gorp T, et al.
Gynecol Oncol
. 2024 Oct;
191:249-258.
PMID: 39461270
Objective: Mirvetuximab soravtansine-gynx (MIRV) is a novel antibody-drug conjugate targeting folate receptor alpha (FRα), which is overexpressed in epithelial ovarian cancer (EOC), with limited expression on normal tissues. This integrated...
9.
Cadzow L, Brenneman J, Tobin E, Sullivan P, Nayak S, Ali J, et al.
Cancer Res
. 2024 Oct;
84(20):3419-3434.
PMID: 39402989
Defects in DNA repair pathways play a pivotal role in tumor evolution and resistance to therapy. At the same time, they create vulnerabilities that render tumors dependent on the remaining...
10.
Tarannum M, Dinh K, Vergara J, Birch G, Abdulhamid Y, Kaplan I, et al.
Sci Adv
. 2024 Jul;
10(28):eadn0881.
PMID: 38996027
Epithelial ovarian cancer (EOC) remains one of the most lethal gynecological cancers. Cytokine-induced memory-like (CIML) natural killer (NK) cells have shown promising results in preclinical and early-phase clinical trials. In...